Irinotecan Hikma

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Hikma, is a Topoisomerase I inhibitor presented as an injection solution for intravenous use. It is used in the treatment of metastatic colorectal cancer in adult patients.

GNH USA supplies Irinotecan Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Hikma is a Topoisomerase I inhibitor indicated for colorectal cancer therapy.

Metastatic colorectal cancer: used as part of combination chemotherapy to improve overall survival. Advanced colorectal cancer: administered intravenously to inhibit tumor cell replication. Colorectal adenocarcinoma with disease progression: employed in regimens for patients who have failed prior therapy.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require medical management. - Nausea and vomiting: typical during and after infusion. - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: temporary hair loss. - Fatigue: generalized tiredness. - Abdominal cramping: discomfort in the stomach area.

Serious or Rare Side Effects: - Severe neutropenic infection: febrile neutropenia requiring hospitalization. - Acute cholinergic syndrome: sweating, salivation, bronchospasm. - Hepatotoxicity: elevated liver enzymes. - Severe mucositis: painful inflammation of the mouth lining. - Hypersensitivity reactions: rash, dyspnea, anaphylaxis. - Tumor lysis syndrome: metabolic disturbances from rapid tumor cell death.

Before initiating therapy, clinicians should assess patient health status and monitor laboratory parameters.

Baseline blood counts: obtain complete blood count and differential. Liver function: evaluate hepatic enzymes and bilirubin. Renal function: assess creatinine clearance for dose adjustments. Concurrent medications: review for agents that may increase toxicity. Pregnancy and lactation: avoid use unless benefits outweigh potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan can interact with several drugs that affect its metabolism or toxicity profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Anticholinesterase agents (e.g., neostigmine): increase risk of cholinergic syndrome. - High‑dose corticosteroids: may exacerbate neutropenia.

Moderate Interactions (Monitor Closely): - UGT1A1 inhibitors (e.g., atazanavir): may raise SN‑38 levels. - Antiemetics containing serotonin antagonists: potential additive nausea control. - Warfarin: monitor INR for altered anticoagulation. - Fluoropyrimidines: increased myelosuppression risk. - Proton pump inhibitors: may affect gastric pH and absorption of oral supportive meds.